This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker(s): BOEHRINGER INGELHEIMWho's the expert?
I come from the perspective of community pulmonary practice over 30 years.
I have treated many bronchiectasis patients over that time and have seen the standard of care continue to evolve.
- Roughly how many patients over the age of 12 do you treat with non-cystic fibrosis bronchiectasis per year? 45
- Are you familiar with the results from the Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis yes. I have reviewed the publicly available literature
Interview Goalto discuss the current treatment landscape and the potential of nerandomilast a therapy being developed by Boehringer Ingelheim for the treatment of interstitial lung diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
